Mark J. Mulvihill (OSI Pharmaceuticals)

-

Location: 123 Nieuwland Science Hall

Oncology Drug Discovery at OSI Pharmaceuticals: The Discovery of a Series of Novel, Highly Potent and Selective Quinolinyl-Derived Imidazopyrazine Insulin-like Growth Factor-I Receptor Inhibitors
He is Associate Director of Chemistry, Oncology at OSI Pharmaceuticals, in Farmingdale, NY.
Mayland Chang